Brevibacillus brevis

Brevibacillus brevis: A Comprehensive Reference Article

1. Identity, Taxonomy, and Classification

1.1 Scientific Name and Nomenclature

Brevibacillus brevis (formerly known as Bacillus brevis) is a Gram-positive, aerobic, motile, spore-forming, rod-shaped bacterium commonly found in soil, air, water, and decaying matter. Cells typically measure 2.1–5.0 μm in length and 0.6–1.0 μm in width, and the species belongs to the family Paenibacillaceae.

In 1900, Bacillus brevis was first described by Migula. During the early 1900s, many other strains were classified as Bacillus brevis on the basis of similar phenotypic characteristics, and consequently the species became a heterogeneous entity. After subsequent studies on B. brevis and related strains, reclassification was performed as novel species of the genera Brevibacillus and Aneurinibacillus on the basis of polyphasic taxonomy. Brevibacillus brevis (Migula 1900) Shida et al. 1996 is the type species of the genus; the new genus was validly published as: Shida O, Takagi H, Kadowaki K, Komagata K. Proposal for two new genera, Brevibacillus gen. nov. and Aneurinibacillus gen. nov. Int J Syst Bacteriol 1996; 46:939–946.

The full taxonomic lineage according to NCBI is: cellular organisms → Bacteria → Bacillati → Bacillota → Bacilli → Bacillales → Paenibacillaceae → Brevibacillus. As of October 2025, the List of Prokaryotic names with Standing in Nomenclature records 34 validly published species in the genus Brevibacillus.

1.2 Synonyms and Related Strains

Bacillus brevis (now often referred to as Brevibacillus parabrevis) ATCC 8185 synthesizes two kinds of antibiotic peptides: the cyclopeptide tyrocidine and linear gramicidin. It is important to note that the specific strain ATCC 8185, which produces the gramicidin/tyrocidine complex best known in pharmaceutical contexts, has been reclassified as Brevibacillus parabrevis, a closely related but distinct species. Brevibacillus brevis sensu stricto refers to the type species (type strain: ATCC 8246) and the broader genus retains B. brevis as its nomenclatural anchor.

The most frequently used biological resource center deposits for strains of Brevibacillus are held at DSM, NRRL, JCM, ATCC, and LMG, among others.

1.3 Morphological and Physiological Characteristics

Brevibacillus brevis is an aerobic (facultatively anaerobic), Gram-positive bacterium that exhibits chemoorganotrophic metabolism, deriving energy from the oxidation of organic compounds. It is catalase-positive, facilitating the decomposition of hydrogen peroxide, and shows variable oxidase activity depending on the strain. Optimal growth occurs at mesophilic temperatures ranging from 25 to 37°C, with an ideal around 30°C, and within a broad pH range of 5.5 to 9.0, optimally at pH 7.0.

Biochemically, B. brevis is catalase positive, amylase negative, casein negative, gelatinase positive, and indole negative; most strains are citrate users. Some strains are capable of oxidizing carbon monoxide aerobically.

B. brevis thrives in diverse natural environments, including soil, seawater, and the intestinal tracts of animals, and is known for its ability to grow on routine media under mesophilic conditions.

1.4 Natural Sources and Environmental Distribution

The organism is commonly found in soil, air, water, and decaying matter. The genus Brevibacillus comprises Gram-positive or Gram-variable bacteria with remarkable environmental adaptability, enabling colonization of diverse ecological niches such as soil, marine environments, and plant and animal hosts. B. brevis spores are also utilized in the fermentation of foods such as soybean paste in the Far East.

1.5 Genomic Characteristics

Genome sizes of sequenced B. brevis strains (excluding strain NEB573) vary from 5.95 to 6.73 Mb, with GC content between 47.0% and 47.5%. Pan-genome analysis demonstrates significant genomic flexibility, with an open architecture comprising 2,855 core gene families (33.08%) and 1,699 distinct genes. Functional annotations indicate that unique genes are enriched in tasks related to DNA repair and environmental adaptation, while core genes predominantly participate in amino acid metabolism and transcription.

Brevibacillus brevis strain FJAT-0809-GLX, a well-characterized biocontrol strain, has a draft genome sequence of 6 Mb comprising 5,677 genes (protein-coding sequences), with an average gene length of 933 bp and a G+C content of 47.30%. Compared with the published B. brevis strain NBRC 100599, 618 specific genes were identified in strain FJAT-0809-GLX.

2. Common Forms and Preparations

Brevibacillus brevis has garnered attention for its potential applications in nutritional and probiotic products. The organism's natural spore-forming capacity is central to its utility in such contexts. Brevibacillus species have been recognized for their robust ability to survive harsh environmental conditions, owing to their spore-forming nature. This resilience has positioned them as potential candidates for use in food and dietary supplements, especially where stability and survivability through the gastrointestinal tract are important.

In pharmaceutical and clinical settings, the most commercially significant preparation derived from B. brevis is tyrothricin, the crude antibiotic mixture extracted from the bacterium. Tyrothricin is a polypeptide antibiotic mixture consisting of approximately 60–80% tyrocidins (cyclic decapeptides) and 20–40% gramicidins (linear pentadecapeptides), produced by the soil bacterium Brevibacillus brevis (formerly Bacillus brevis). Primarily employed as a topical agent due to its cytotoxicity when administered systemically, tyrothricin exhibits broad-spectrum activity against Gram-positive bacteria, certain fungi, and some viruses by disrupting microbial cell membranes, leading to leakage and cell death.

In agricultural and food science contexts, the organism is prepared as a spore-based microbial agent for use in animal feeds and as a biocontrol preparation. It can secrete large amounts of secondary metabolites, which are important for controlling pathogens. In these applications, the bacterium is typically fermented, harvested as a spore concentrate, and dried into a powder or granule for mixing with feed or soil.

3. Historical and Traditional Use

3.1 Discovery in the Early Antibiotic Era

It was independently discovered at the end of the 1930s and the beginning of the 1940s that various strains of the soil bacterium Brevibacillus brevis (formerly Bacillus brevis) produced substances inhibiting a range of pathogenic bacteria and even fungi. The species appeared to be producing a variety of linear and cyclic peptides using nonribosomal protein synthetases.

Discovered in 1939 by microbiologist René Dubos at the Rockefeller Institute through culturing soil samples on whole bacterial particles, tyrothricin represents the first clinically tested antibiotic derived from a bacterium, predating widespread penicillin use and helping to launch the modern antibiotic era. Dubos screened numerous soil samples, particularly from a New Jersey cranberry bog, culturing them selectively on media containing staphylococci, pneumococci, and streptococci to enrich for antagonistic bacteria. He isolated a promising Gram-positive, spore-forming aerobic bacillus, later identified as Bacillus brevis.

After years and countless soil samples, Dubos isolated a bacterium, Bacillus brevis, that disintegrated staphylococci, and from which he was able to isolate gramicidin and tyrothricin. His announcement at a conference at New York's Waldorf Astoria in 1939 proved a sensation, as he explained that a small quantity of the grey powder was sufficient to protect vast numbers of mice against pneumonia and streptococcal infections.

Some two years after Dubos's announcement, the bacterial species producing the antibiotic was definitively identified as Bacillus brevis (now Brevibacillus brevis) and tyrothricin was shown to be comprised of two antibiotic substances, gramicidin and tyrocidine.

Despite being hailed in 1939 as "a hundred thousand times" more powerful than the sulpha drugs, gramicidin proved highly toxic when administered intravenously, and although it was widely used during World War II to treat wounds and other topical infections it was soon eclipsed by streptomycin. Nonetheless, gramicidin was the first antibacterial agent to emerge from systematic scientific research and, together with tyrothricin, its less pure form, the first to be produced commercially and used clinically.

3.2 Wartime Wound Care and Pre-Antibiotic Topical Use

Cyclic β-sheet decapeptides, such as tyrocidines and gramicidin S, were among the first antibiotics in clinical application. Gramicidin-based preparations derived from B. brevis cultures were applied topically in World War II-era wound management, representing a pivotal bridge between pre-antibiotic era wound care and the modern pharmaceutical era. It was independently discovered at the end of the 1930s and the beginning of the 1940s that various strains of the soil bacterium Brevibacillus brevis produced substances inhibiting a range of pathogenic bacteria and even fungi.

3.3 East Asian Fermentation Traditions

Brevibacillus brevis spores are utilized in the fermentation of foods such as soybean paste in the Far East. Within this tradition, B. brevis and related soil-dwelling bacilli participate in the natural microbial consortia that drive fermentation of legume-based foods. The documentation of this as a deliberate, isolated traditional use of B. brevis specifically—as distinct from broad communities of fermenting bacilli—is, however, limited in the peer-reviewed literature. No formal ethno-pharmacological records of isolated B. brevis preparations for therapeutic purposes in traditional medicine systems have been identified in the peer-reviewed literature searched.

4. Key Constituents and Active Compounds

4.1 Tyrothricin Complex: Gramicidins and Tyrocidines

This species is particularly notable as the primary producer of the peptide antibiotics gramicidin and tyrocidine, which were the first such compounds isolated from bacteria and have significant antibacterial activity.

Tyrothricin, the first peptidic antibiotic clinically used in humans (1939), is a mixture of cyclic tyrocidins (70–80%) and linear gramicidin D (20–25%), both produced by Bacillus brevis. Gramicidin D is a mixture of three compounds—gramicidin isoforms A, B, and C—present in a 7:1:2 ratio, respectively. Gramicidins are synthesized non-ribosomally by a multienzyme complex. These antimicrobial peptides (AMPs) contain D-amino acids, which allow the peptides to adopt a β-helical structure and interact with bacterial membranes.

Gramicidin (also called gramicidin D) is a mix of ionophoric antibiotics, gramicidin A, B and C, which make up about 80%, 5%, and 15% of the mix, respectively; each has two isoforms, so the mix has six different types of gramicidin molecules. They can be extracted from Brevibacillus brevis soil bacteria. Gramicidins are linear peptides with 15 amino acids.

Gramicidin A (gA), a fifteen-residue linear peptide, is composed of alternating D- and L-amino acids; gA folds into a β-helix with an internal pore. The length of the β-helix matches well with one leaflet of a membrane; inter-leaflet dimerization yields a transmembrane channel.

4.2 Additional Bioactive Compounds

Among the secondary metabolites identified from B. brevis, tyrocidine, gramicidin, gratisin, and edeine have been successively isolated and characterized. Comparative genomics analyses reveal that only one non-ribosomal peptide synthetase (NRPS) gene cluster annotated as edeine is present in the core genome of B. brevis; UHPLC-MS/MS detection results show that edeine B and edeine A are principal antibacterial peptides in some B. brevis strains, confirming edeine as a key antibacterial peptide of the species.

Members of the genus Brevibacillus have been demonstrated to produce a variety of bioactive compounds including polyketides, lipopeptides, and bacteriocins. Research has demonstrated that tyrocidines, a well-known family of cyclodecapeptides of great structural variability, are the main products of all investigated strains, with a novel class of pentapeptides—designated brevipentins—produced by B. brevis, B. schisleri, and B. porteri.

Because Brevibacillus spp. produce various bioactive peptides, genomic analysis of B. brevis HK544 revealed that the genome contains 14 gene clusters for nonribosomal peptide synthetases and polyketide synthases, and for bacteriocins, terpenes, siderophores, and lanthipeptides.

4.3 Enzymes

Extracellular proteases from B. brevis, such as the thermotolerant alkaline protease from strain BT2, exhibit optimal activity at pH 9–10 and temperatures up to 60°C, enabling applications in hydrolysis processes like detergent formulations and leather processing. α-Amylases produced by strains like MTCC 7521 hydrolyze starch efficiently at neutral pH and 50–60°C, supporting uses in food processing and biofuel production when utilizing agro-waste carbon sources like potato peels.

Additionally, a novel endochitinase (85 kDa, pI 5.5) with optimal activity at pH 8.0 and 60°C demonstrates antifungal properties by degrading chitin in fungal cell walls, contributing to biocontrol against phytopathogens.

Brevibacillus brevis isolated from soil has been assessed for enzyme production, antibacterial activity, and anticancer activity; the organism was found to be a promising source of amylase enzymes, antibacterial as well as anticancer compounds. These latter findings are preliminary and are restricted to laboratory investigations.

5. Mechanisms of Action

5.1 Ion Channel Formation by Gramicidin

Gramicidin kills bacteria by increasing the permeability of their cell membranes to monovalent cations, thus destroying the intracellular ion gradient. Gramicidin A (gA) is an antibiotic peptide produced by Bacillus brevis that can dimerize across lipid bilayers to form a monovalent cation channel. Inorganic monovalent ions such as potassium (K⁺) and sodium (Na⁺) can travel through these pores freely via diffusion. This destroys vital ion concentration differences, i.e., ion gradients, between membranes, thereby killing the cell via various effects.

Gramicidins and related polypeptides act as channels and increase the permeability of the bacterial cell membrane when incorporated, thus destroying the ion gradient between the cytoplasm and the extracellular environment. The linear peptide gramicidin forms prototypical ion channels specific for monovalent cations and has been extensively used to study the organization, dynamics, and function of membrane-spanning channels.

5.2 Membrane Disruption by Tyrocidine

Gramicidin S is a cyclic decapeptide secreted by Bacillus brevis, known for its potent antimicrobial action against various Gram-negative and Gram-positive bacteria as well as pathogenic fungi, although its high hemolytic activity limits its use primarily to topical applications. Its antimicrobial efficacy is attributed to its ability to disrupt the lipid bilayer integrity of bacterial membranes.

The cyclic peptide antibiotic tyrocidine, synthesized by Bacillus brevis, inhibits RNA synthesis in an in vitro transcriptional system by forming a complex with the DNA. Tyrocidine unwinds superhelical plasmids in vitro at low peptide:DNA ratios; at higher peptide concentrations, the DNA is packed tightly, leading to apparent nuclease stability of the complex and inhibition of RNA synthesis.

Research results shed new light on the multifaceted antibacterial mechanisms of these antibiotics and explain why resistance to them is virtually nonexistent. This multifactorial mode of action—simultaneously disrupting membrane integrity, distorting membrane protein localization, and interfering with DNA—is proposed as the reason for the absence of clinically relevant resistance to these compounds.

5.3 Role in Sporulation

Evidence has been presented that the two peptide antibiotics tyrocidine and linear gramicidin, produced by Bacillus brevis ATCC 8185, are required for the induction of sporulation in the producer organism. Gramicidin, produced during the transition from vegetative growth to sporulation, inhibits RNA synthesis by purified RNA polymerase by interfering with the binding of RNA polymerase to DNA. This effect seems to involve the destabilization of the "open" RNA polymerase–DNA complex, a mode of action consistent with the control of promoter selection.

5.4 Biosynthesis: Non-Ribosomal Peptide Synthesis

The nonribosomal biosynthesis of tyrocidine is via an enzymatic assembly consisting of three peptide synthetase proteins, TycA, TycB, and TycC, which contain 10 modules. Gramicidins are also synthesized non-ribosomally by a multienzyme complex, and these AMPs contain D-amino acids, which allow the peptides to adopt a β-helical structure and interact with bacterial membranes.

6. Scientific Evidence by Area of Use

6.1 Antimicrobial Activity

The AMPs produced by B. brevis are active against Gram-positive bacteria (with the exception of Bacillus) and some Gram-negative organisms (such as Neisseria sp.). Gramicidins work as antibiotics against Gram-positive bacteria like Bacillus subtilis and Staphylococcus aureus, but not well against Gram-negative ones like E. coli.

The evidence base for the antibacterial activity of gramicidin and tyrocidine derived from B. brevis consists predominantly of in vitro and biochemical laboratory studies accumulated over more than eight decades. Tyrothricin was shown to have activity against Gram-positive cocci but not Gram-negative bacteria, and it could protect white mice from very high inocula of various strains of Streptococcus with only small amounts of crude extract or purified active substance. These animal-model data were established in the 1930s–1940s and represent the original preclinical evidence base.

Evidence strength: Strong in vitro and historical preclinical evidence. The topical clinical use of gramicidin and tyrothricin has been established for decades, principally in combination topical antibiotic formulations. No modern randomized controlled clinical trials (RCTs) specifically evaluating B. brevis as a whole organism supplement for infection treatment were identified in the peer-reviewed literature.

6.2 Biocontrol of Plant Pathogens

Various Brevibacillus species have been recognized as rich sources of antimicrobial peptides, and several strains have been studied as biocontrol agents against plant pathogens. The B. brevis HK544 strain, isolated from soil, exhibited antifungal and antibacterial activities against plant pathogens such as Botrytis cinerea, Phytophthora infestans, and Erwinia amylovora.

B. brevis HNCS-1, isolated from tea garden soil, demonstrated an antagonistic effect against five types of pathogens of tea diseases, namely Gloeosporium theae-sinensis, Elsinoe leucospira, Phyllosticta theaefolia, Fusarium sp., and Cercospora theae.

Studies showed that B. brevis FJAT-0809-GLX had significant inhibitory effects on plant pathogens such as Ralstonia solanacearum, Fusarium oxysporum, and Escherichia coli K88.

Examination of biosynthetic gene clusters identified multiple antimicrobial compounds, such as gramicidin and tyrocidine, which have been reported to exhibit both antibacterial and antifungal activities, thereby underscoring the broad-spectrum biocontrol potential of B. brevis. These findings endorse the application of biocontrol in sustainable plant disease management.

Evidence strength: Laboratory and greenhouse-level evidence is well-established. Genomic studies support the mechanistic basis of biocontrol activity. There are no published large-scale field trials in peer-reviewed literature identified here that translate these results to human-health or probiotic supplement claims.

6.3 Probiotic and Gut Microbiome Applications

Recent scientific interest in Brevibacillus centers around certain strains studied for their antimicrobial and probiotic properties. Some research indicates that these bacteria may help promote a healthy gut microbiome, inhibit pathogenic microorganisms, and support immune function. However, these claims currently rest predominantly on preliminary data.

Preliminary in vitro and animal studies suggest that Brevibacillus-derived compounds can possess antibacterial and antifungal activities, contributing to improved gut health and possibly aiding in the maintenance of digestive balance.

It is important to distinguish that most of the well-documented dietary probiotic research for the genus involves Brevibacillus laterosporus in animal feed studies rather than B. brevis in human probiotic research. No published human clinical trials specifically evaluating oral Brevibacillus brevis supplementation for gut health outcomes were identified in the peer-reviewed literature.

6.4 Animal Feed Supplementation Studies

The most robust current body of experimental evidence concerning Brevibacillus dietary supplementation involves the related species B. laterosporus in poultry models. These data are relevant for contextualizing research directions for the genus, though they are not directly transferable to human supplementation with B. brevis.

Dietary supplementation with B. laterosporus significantly enhanced the oxidative stress resistance of broiler serum by decreasing malondialdehyde (MDA) levels and increasing glutathione peroxidase (GSH-PX) and total antioxidant capacity (T-AOC). Analysis demonstrated significant increases in α-diversity indices in the supplemented group, with an increased relative abundance of Firmicutes and a decreased relative abundance of Bacteroidetes and Proteobacteria.

Evidence strength: Animal (poultry) evidence is promising but of limited direct relevance to human health outcomes. No human RCTs have been published for dietary B. brevis supplementation in the context of gut microbiome modulation.

6.5 Potential Anticancer Activity

In a laboratory study, Brevibacillus brevis isolated from soil was assessed for antibacterial activity and anticancer activity, and the organism was found to be a promising source of antibacterial as well as anticancer compounds. This represents preliminary, in vitro screening-level evidence only.

Evidence strength: Strictly preliminary. No human studies, animal tumor models specific to B. brevis, or mechanistic clinical data were identified. These findings should not be interpreted as evidence of clinical anticancer benefit.

6.6 Enzyme Production and Biotechnological Applications

Brevibacillus brevis LABIM17 is a bacterial isolate with biotechnological potential. Its draft genome sequence exhibits 12 clusters involved in the production of secondary metabolites, which are likely responsible for its antimicrobial activity against several human and plant pathogens.

Because of its robust sporulation, metabolic versatility, and strong antimicrobial activity, B. brevis has attracted attention as a promising biocontrol agent for sustainable agriculture, offering an environmentally friendly alternative to chemical pesticides. Its biocontrol efficacy derives mainly from the biosynthesis of diverse antimicrobial metabolites—including enzymes such as cellulase and chitosanase—and non-ribosomal peptides.

7. Body Systems and Health Areas of Association

7.1 Integumentary System (Skin and Mucous Membranes)

The most clinically validated use of B. brevis-derived products is topical antimicrobial application. The use of gramicidins and other polypeptides is limited to topical applications. They act as channels and increase the permeability of the bacterial cell membrane when incorporated, thus destroying the ion gradient. In animals and humans, this activity, at concentrations lower than needed to achieve the bacterial-killing effect, induces hemolysis. Thus, topical applications require the skin or mucous membrane surface to be intact to prevent systemic entry.

7.2 Immune System

Lipopeptides produced by Brevibacillus are non-ribosomally synthesized surface-active compounds with antimicrobial, antitumor, and immune-stimulatory activities. These findings are based on in vitro characterization of isolated compounds and have not been substantiated in human clinical trials directed at immune outcomes.

7.3 Gastrointestinal System

The unique antimicrobial peptides of B. brevis have been proposed to help support a balanced intestinal microbiome, which is considered essential for overall wellness and immune function. However, as noted above, the evidence supporting this claim in humans is not established at the level of clinical trials.

7.4 Agricultural and Environmental Health

In plant science, coinoculation of white clover (Trifolium repens) with arbuscular mycorrhizal fungi (AMF) G. mosseae and the plant-growth-promoting rhizobacterium (PGPR) B. brevis had additive effects on plant growth, accumulation of nutrient elements, and reduction of cadmium toxicity. This PGPR strain also stimulated nodulation on roots by native rhizobia present in the soil, with the observed effects suggested to be due to the indole acetic acid produced by PGPR bacteria. These effects are relevant to food quality and environmental sustainability but are not direct human health interventions.

8. Dosage Forms and Reported Dosages

Brevibacillus brevis as an intact organism does not have established or standardized human supplemental dosages documented in clinical trials. The organism's bioactive compounds, however, have been characterized in specific contexts:

• Tyrothricin (topical pharmaceutical): Tyrothricin is a polypeptide antibiotic mixture consisting of approximately 60–80% tyrocidins and 20–40% gramicidins, formulated in topical preparations (lozenges, creams, and throat sprays) for use in oral and pharyngeal mucosa infections. Concentrations and dosing for these preparations are regulated by national pharmacopoeias and are administered as topical products, not dietary supplements.
• Animal feed supplementation (B. laterosporus): In the poultry study referenced, Brevibacillus laterosporus supplementation was studied at varying inclusion levels in broiler feed; specific dosage data cited in that publication would require direct reference to the study protocol, which reports outcomes rather than definitive recommended human-equivalent doses.
• Gramicidin topical: The yield of linear gramicidin produced by the standard method under experimental conditions was 3.11 μg/ml, illustrating the small concentrations involved in production contexts.

No peer-reviewed publications were identified that report specific oral dosages of whole Brevibacillus brevis organisms (as CFUs or otherwise) for human dietary supplement use in controlled clinical trials.

9. Safety Considerations

9.1 Biosafety Classification

The Canadian risk group classification for Brevibacillus is Risk Group 1, indicating it is not classified as a security-sensitive biological agent, is not a terrestrial animal pathogen under the Canadian Food Inspection Agency's authority, and requires only Containment Level 1.

9.2 Rarity of Human Infection

B. brevis is rarely associated with infectious diseases. Brevibacillae are organisms found in the environment and soil. Brevibacillus species are rarely pathogenic but can cause severe infections in immunocompromised hosts, intravenous drug users, victims of burns and physical trauma, dialysis patients, and patients who have undergone recent orthopedic and neurosurgical procedures.

For the specific case of Brevibacillus brevis, there is a paucity of literature describing infections by this organism in humans. A documented case of B. brevis meningitis and bacteremia has been reported in the medical literature (PMC7397378), representing one of very few published cases of systemic human infection by this specific species.

9.3 Systemic Toxicity of Derived Compounds

In animals and humans, the ion-channel activity of gramicidin, at concentrations lower than needed to achieve the bacterial killing effect, induces hemolysis. Thus, topical applications require the skin or mucous membrane surface to be intact to prevent systemic entry. Gramicidin's hemolytic toxicity has historically precluded its use as a systemic antibiotic.

Despite being hailed as highly potent, gramicidin proved highly toxic when administered intravenously. This systemic toxicity is a defining pharmacological limitation of the compounds derived from B. brevis, and it is the basis for their restriction to topical use in pharmaceutical contexts.

9.4 Spore-Forming Nature and Gastrointestinal Survival

The spore-forming nature of Brevibacillus species confers robust ability to survive harsh environmental conditions. This resilience positions them as potential candidates for use in food and dietary supplements, especially where stability and survivability through the gastrointestinal tract are important. However, this same resilience means that once introduced, spores may persist in the gastrointestinal environment longer than vegetative bacteria, with unknown long-term implications in human subjects, as no chronic human safety data from controlled trials have been identified.

9.5 Absence of Established Breakpoints

Currently, there are no reported antibiotic susceptibility breakpoints for Brevibacillus spp. This means that in the rare event of a clinical infection, antibiotic selection is challenging and empiric. This is a relevant safety consideration for immunocompromised individuals who might be administered live Brevibacillus preparations.

9.6 Absence of Established Human Clinical Safety Data for Supplemental Use

No published human clinical trials with defined safety endpoints, adverse event monitoring, or pharmacokinetic characterization of oral Brevibacillus brevis supplementation were identified in the peer-reviewed literature. The safety profile in healthy human supplementation contexts therefore cannot be formally characterized based on available clinical evidence. All safety-relevant data identified pertain either to the isolated pharmacological compounds (gramicidin, tyrocidine) applied topically, or to rare case reports of infection in vulnerable populations.

10. Summary and Evidentiary Assessment

Brevibacillus brevis is a scientifically significant soil bacterium whose primary historical and pharmaceutical importance lies in its role as the natural source of the tyrothricin antibiotic complex—gramicidin and tyrocidine—which were the first microbially derived antibiotics to enter clinical use, doing so during the late 1930s and World War II. The mechanistic underpinnings of these compounds are well-characterized through decades of biochemical and structural research: they act predominantly by forming ion channels in bacterial cell membranes (gramicidin) and disrupting membrane lipid bilayers and DNA function (tyrocidines). Their clinical use remains restricted to topical pharmaceutical preparations due to systemic hemolytic toxicity.

As a dietary supplement or probiotic candidate in its own right, B. brevis (the intact organism) occupies a more speculative position. The available evidence consists primarily of in vitro antimicrobial studies, genomic analyses identifying biosynthetic gene clusters, agricultural biocontrol applications, and animal feed studies mostly involving related species such as B. laterosporus. Human clinical trial evidence for B. brevis as a dietary supplement—for any indication, including gut health, immunity, or infection prevention—does not exist in the current peer-reviewed literature. Claims about probiotic benefits, immune modulation, or traditional therapeutic use as a whole-organism supplement are not substantiated by clinical evidence of a quality sufficient to draw firm conclusions.

The organism is considered a biosafety Risk Group 1 microorganism, is rarely associated with human infection, and presents the greatest infectious risk for immunocompromised individuals. The pharmacologically active compounds it produces are, under normal circumstances, retained within the microbial context and are not absorbed systemically through intact gut mucosa.

References

• Comparative Genomic Analysis of Brevibacillus brevis: Insights into Pan-Genome Diversity and Biocontrol Potential — PMC (2025)
• A Case of Brevibacillus brevis Meningitis and Bacteremia — PMC
• Draft Genome Sequence of Biocontrol Bacterium Brevibacillus brevis Strain FJAT-0809-GLX — Genome Announcements, PMC (2013)
• Genome Sequence of Brevibacillus brevis HK544, an Antimicrobial Bacterium Isolated from Soil in Daejeon, South Korea — PMC (2021)
• Draft Genome Sequence of Brevibacillus brevis LABIM17, a Biotechnologically Important Antimicrobial-Producing Bacterium — PMC (2022)
• Characterization and Antimicrobial Studies of Iturin-Like and Bogorol-Like Lipopeptides From Brevibacillus spp. — Frontiers in Microbiology, PMC (2021)
• Brevibacillus brevis HNCS-1: a Biocontrol Bacterium Against Tea Plant Diseases — Frontiers in Microbiology, PMC (2023)
• Brevibacillus Laterosporus Osteomyelitis and Hardware Infection in a Young, Immunocompetent Patient — PMC (2024)
• Brevibacillus Laterosporus Bacteremia in an Adult — PMC (2020)
• Antibacterial Action of Gramicidin S and Tyrocidines in Relation to Active Transport, In Vitro Transcription, and Spore Outgrowth — PMC
• Antibiotic Antagonist: The Curious Career of René Dubos — PMC (2020)
• Origins of Combination Therapy for Tuberculosis: Lessons for Future Antimicrobial Development — PMC (2017)
• The Multifaceted Antibacterial Mechanisms of the Pioneering Peptide Antibiotics Tyrocidine and Gramicidin S — mBio, PubMed (2018)
• Gramicidin D Conformation, Dynamics and Membrane Ion Transport — PubMed (1999)
• Functions of the Peptide Antibiotics Tyrocidine and Gramicidin: Induction of Conformational and Structural Changes of Superhelical DNA — PubMed (1982)
• Induction of Sporulation in Bacillus brevis: Dependence on the Presence of Peptide Antibiotics Tyrocidine and Linear Gramicidin — PubMed (1982)
• Enhancement of Linear Gramicidin Expression from Bacillus brevis ATCC 8185 by Casein Peptide — PubMed (2005)
• Gramicidin A in Asymmetric Lipid Membranes — Biomolecules, PMC (2024)
• Investigation of the Potential of Brevibacillus spp. for the Biosynthesis of Nonribosomally Produced Bioactive Compounds — PMC (2024)
• Brevibacillus brevis — ScienceDirect Topics (Pharmacology)
• Brevibacillus brevis — ScienceDirect Topics (Agricultural and Biological Sciences)
• Gramicidin — ScienceDirect Topics (Immunology and Microbiology)
• The Gramicidin Ion Channel: A Model Membrane Protein — Biochimica et Biophysica Acta, ScienceDirect (2007)
• Brevibacillus brevis Taxonomy — NCBI Taxonomy Browser
• Genus Brevibacillus — List of Prokaryotic names with Standing in Nomenclature (LPSN/DSMZ)
• Brevibacillus brevis — Wikipedia
• Bioprospecting of Brevibacillus brevis Isolated from Soil — Bentham Science / EurekaSelect
• Effect of Dietary Supplementation with Brevibacillus laterosporus on Broiler Growth Performance, Meat Quality and Gut Microbiome — Frontiers in Microbiology, PMC (2025)
• Dietary Effect of Brevibacillus laterosporus S62-9 on Chicken Meat Quality, Amino Acid Profile, and Volatile Compounds — PMC (2023)